Intensity Therapeutics Q1 net loss narrows on lower R&D costs

Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc.

INTS

0.00


Overview

  • US biotech firm's Q1 net loss narrowed yr/yr on lower R&D expenses

  • Company ended Q1 with $10.2 mln in cash and cash equivalents

  • Plans to resume enrollment in INVINCIBLE-3 and INVINCIBLE-4 clinical trials in 2026


Outlook

  • Intensity Therapeutics plans to resume INVINCIBLE-4 Study enrollment in Switzerland in Q2 2026

  • Company expects to initiate INVINCIBLE-4 Study enrollment in France in Q2 or Q3 2026

  • Intensity Therapeutics will resume INVINCIBLE-3 Study enrollment in limited U.S. sites by Q3 2026


Result Drivers

  • LOWER R&D SPENDING - Research and development expenses fell due to reduced costs from pausing new site activations and patient enrollment in the INVINCIBLE-3 study

  • EARLY TRIAL DATA - Preliminary results from the INVINCIBLE-4 study showed higher pathological complete response rates and fewer severe adverse events for INT230-6 plus standard of care compared to standard of care alone


Company press release: ID:nPnbRhMP0a


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Basic EPS

-$0.96

Q1 Operating Income

-$2.53 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • Wall Street's median 12-month price target for Intensity Therapeutics Inc is $31.00, about 495% above its May 6 closing price of $5.21


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.